Table 3.

Abnormal results of the dRVVT test depending on anticoagulant treatment.

Anticoagulant	Proportion of patients with abnormalities in the dRVVT, n
	Controls	aPLneg	aPLlow	aPLhigh
None or discontinued	2% (34)	4% (36)	8% (14)	32% (23)
Rivaroxaban	–	66% (301)*	79% (73)*	84% (31)*
Apixaban	–	7% (7)	12% (3)	33% (5)
VKA	–	19% (107)*	27% (32)*	64% (54)*
LMWH	–	6% (14)	17% (10)	38% (13)

Patients with a prolonged dRVVT screen and a dRVVT ratio > 1.2 were considered abnormal.

dRVVT, dilute Russell viper venom time; LMWH, low molecular weight heparin; NS, not significant; VKA, vitamin K antagonist.

*Significantly higher in comparison to the cohort with no or discontinued anticoagulants (P < 10^–4 for all significantly different comparisons, calculated using the chi-squared test).